Compare DQ & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DQ | ANIP |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2010 | 1999 |
| Metric | DQ | ANIP |
|---|---|---|
| Price | $20.84 | $74.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $28.91 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 595.1K | 296.8K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $70.27 | $23.05 |
| Revenue Next Year | $34.95 | $14.08 |
| P/E Ratio | ★ N/A | $22.87 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $12.41 | $56.71 |
| 52 Week High | $36.59 | $99.50 |
| Indicator | DQ | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 48.91 |
| Support Level | $20.47 | $72.43 |
| Resistance Level | $25.90 | $77.47 |
| Average True Range (ATR) | 0.91 | 2.07 |
| MACD | 0.02 | 0.41 |
| Stochastic Oscillator | 15.49 | 57.59 |
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.